Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Transplant Proc ; 49(10): 2333-2339, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29198673

ABSTRACT

BACKGROUND: Total pancreatectomy (TP) is offered as a last treatment option for pain relief in patients with chronic pancreatitis. Concurrent islets autotransplantation (TP-IAT) may improve glucose control. METHODS: We analyzed results in 20 recent patients who underwent TP-IAT at The University of Chicago. The median observation period was 28 months (2-38). Data were collected prospectively then analyzed retrospectively. RESULTS: The number of patients requiring opioids daily for pain control decreased from 16 (80%) prior to surgery to 2 (13%) 1 year after, with only 1 (6.5%) patient experiencing persistent phantom pancreatic pain. Opioid requirements decreased from a median 56.3 (0-240) morphine equivalent dose to 5 (0-130) on day 75 and to 0 (0-30) at 1-year follow up. Five patients (25%) completely stopped insulin support prior to day 75 while maintaining hemoglobin A1c of 5.9% (5-6.3). Eight (53%) patients were insulin free at 1 year with A1c of 6% (5.5-6.8) and a similar rate persisted in next 2 years. For the remaining patients, the more islet function that was preserved, the less insulin they required and A1c was closer to optimal. Quality of Life (QoL) measured by SF36 Physical (PCS) and Mental (MCS) Component Score improved on day 75 (P < .001) and maintained improvement later on. Both PCS and MCS improved regardless of whether patient requires insulin support or not. CONCLUSIONS: Improvements of QoL with pain resolution and good glucose control can be achieved after TP-IAT in properly selected patients with CP and intractable pain, regardless of patient insulin support status.


Subject(s)
Blood Glucose , Islets of Langerhans Transplantation/methods , Pain, Postoperative/epidemiology , Pancreatectomy/adverse effects , Pancreatitis, Chronic/surgery , Quality of Life , Adult , Female , Humans , Islets of Langerhans Transplantation/adverse effects , Male , Middle Aged , Pain Management , Pancreatectomy/methods , Retrospective Studies , Transplantation, Autologous , Treatment Outcome
2.
Transplant Proc ; 49(10): 2340-2346, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29198674

ABSTRACT

BACKGROUND: BETA-2 score using a single fasting blood sample was developed to estimate beta-cell function after islet transplantation (ITx) and was validated internally by a high ITx volume center (Edmonton). The goal was to validate BETA-2 externally, in our center. METHODS: Areas under receiver operating characteristic curves (AUROCs) were obtained to see if beta score or BETA-2 would better detect insulin independence and glucose intolerance. RESULTS: We analyzed values from 48 mixed meal tolerance tests (MMTTs) in 4 ITx recipients with a long-term follow-up to 140 months (LT group) and from 54 MMTTs in 13 short-term group patients (ST group). AUROC for no need for insulin support was 0.776 (95% confidence interval [CI] 0.539-1, P = .02) and 0.922 (95% CI 0.848-0.996, P < .001) for beta score and 0.79 (95% CI 0.596-0.983, P = .003) and 0.941 (95% CI 0.86-1, P < .001) for BETA-2, in LT and ST groups, respectively, and did not differ significantly. In LT group BETA-2 score ≥ 13.03 predicted no need for insulin supplementation with sensitivity of 98%, specificity of 50%, positive predictive value (PPV) of 93%, and negative predictive value (NPV) of 75%. In ST group the optimal cutoff was ≥13.63 with sensitivity of 92% and specificity, PPV, and NPV 82% to 95%. For the detection of glucose intolerance BETA-2 cutoffs were <19.43 in LT group and <17.23 in ST group with sensitivity > 76% and specificity, PPV, and NPV > 80% in both groups. CONCLUSION: BETA-2 score was successfully validated externally and is a practical tool allowing for frequent and reliable assessments of islet graft function based on a single fasting blood sample.


Subject(s)
Blood Glucose/analysis , C-Peptide/analysis , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Islets of Langerhans Transplantation , Adult , Area Under Curve , Diabetes Mellitus, Type 1/surgery , Female , Glycated Hemoglobin/analysis , Humans , Male , Middle Aged , Predictive Value of Tests , ROC Curve
3.
Hernia ; 20(5): 649-57, 2016 10.
Article in English | MEDLINE | ID: mdl-27115766

ABSTRACT

PURPOSE: Several variations in the anatomy and injury of the lateral femoral cutaneous nerve (LFCN) have been studied since 1885. The aim of our study was to analyze the available data on the LFCN and find a true prevalence to help in the planning and execution of surgical procedures in the area of the pelvis, namely inguinal hernia repair. METHODS: A search of the major medical databases was performed for LFCN anatomy. The anatomical data were collected and analyzed. RESULTS: Twenty-four studies (n = 1,720) were included. The most common pattern of the LFCN exiting the pelvis was medial to the Sartorius as a single branch. When it exited in this pattern, it did so on average 1.90 cm medial to the anterior superior iliac spine (ASIS). CONCLUSIONS: The LFCN and its variations are important to consider especially during inguinal hernia repair, abdominoplasty, and iliac bone grafting. We suggest maintaining a distance of 3 cm or more from the ASIS when operating to prevent injury to the LFCN.


Subject(s)
Femoral Nerve/anatomy & histology , Groin/innervation , Hernia, Inguinal/surgery , Herniorrhaphy/adverse effects , Nerve Compression Syndromes/etiology , Femoral Neuropathy , Humans , Ilium/surgery , Pelvis/innervation , Thigh/innervation
SELECTION OF CITATIONS
SEARCH DETAIL
...